Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/245 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME11709108
PMID: | 11709108
LR: | 20051116
CED: | 20011115
DCO: | 20020201
Autoren: | Hochberg MC
Titel: | What a difference a year makes: reflections on the ACR recommendations for the medical management of osteoarthritis.
Quelle: | Current rheumatology reports; VOL: 3 (6); p. 473-8 /200112/
PM: | Print
SU: | IM
Sprache: | English
CY: | United States
JID: | 100888970
ISSN: | 1523-3774
Institution: | Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, and the Maryland Veterans Affairs Health Care System, 10 S. Pine Street, MSTF 8-34, Baltimore, MD 21201, USA. mhochberg@umaryland.edu
DT: | Journal Article; Review
RN: | 52
Schlagwörter
CT: | ACETAMINOPHEN/therapeutic use; ACUPUNCTURE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/*therapeutic use; COMPLEMENTARY THERAPIES; CYCLOOXYGENASE INHIBITORS/*therapeutic use; DIETARY SUPPLEMENTS; HUMANS; OSTEOARTHRITIS, HIP/*drug therapy; OSTEOARTHRITIS, HIP/therapy; OSTEOARTHRITIS, KNEE/*drug therapy; OSTEOARTHRITIS, KNEE/therapy
CTG: | ACETAMINOPHEN/therapeutische Anwendung; AKUPUNKTUR; ANTIPHLOGISTIKA, NICHTSTEROIDALE/*therapeutische Anwendung; KOMPLEMENTÄRE THERAPIEVERFAHREN; CYCLOOXYGENASEINHIBITOREN/*therapeutische Anwendung; NAHRUNGSERGÄNZUNGSMITTEL; MENSCH; OSTEOARTHROSE, HÜFT-/*Arzneimitteltherapie; OSTEOARTHROSE, HÜFT-/Therapie; OSTEOARTHROSE, KNIE/*Arzneimitteltherapie; OSTEOARTHROSE, KNIE/Therapie
TE: | Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Acetaminophen/103-90-2
CR: | 103-90-2
AB: | Since the publication in 2000 of the updated American College of Rheumatology (ACR) recommendations for the medical management of patients with lower limb osteoarthritis (OA), additional recommendations, newer epidemiologic studies, systematic reviews, and clinical trials have been published. The results of these reviews, studies, and trials, which highlight the greater efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) for controlling pain and the potential serious upper gastrointestinal toxicity of acetaminophen, require us to reassess the use of acetaminophen as the first-line pharmacologic agent for all patients with knee OA. Furthermore, the documented efficacy of glucosamine for pain relief and function improvement in patients with knee OA, with an effect size that is comparable with that of NSAIDs, requires us to reassess the use of glucosamine as a potential first-line agent at least for patients with knee OA who have mild-to-moderate pain. The availability of the cyclo-oxygenase 2 (COX-2)-specific inhibitors and their documented greater safety relative to traditional dual-inhibitor NSAIDs with regard to serious upper gastrointestinal toxicity lead us to reassess the use of traditional NSAIDs in patients with OA, especially in those at increased risk for such adverse events. The COX-2-specific inhibitors cost less than the combination of a generic NSAID plus a proton-pump inhibitor. The results of ongoing and future studies, especially of structure-modifying anti- osteoarthritis drugs, will lead to further reassessment and updating of recommendations for the medical management of patients with knee OA. Hopefully, the use of such recommendations will improve the outcomes for patients with this debilitating chronic condition.

» Volltext »
» Fenster schließen »